Clinical Trial

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2024 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A multicenter, randomized, controlled clinical study comparing the efficacy and safety of allogeneic hematopoietic stem cell transplantation with decitabine-Fludarabine- busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as pretreatment regimens for the treatment of acute myeloid leukemia in adults with MR gene abnormalities
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-01; most recent amendment 2024-06-02.
Trial Details
NCT Number NCT06297772
Lead Sponsor Ruijin Hospital
Conditions AML, Adult
Enrollment 220 participants
Start Date 2024-06-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2024-06-04